These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32253663)

  • 1. Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation.
    Arai S; Kamijo T; Takezawa Y; Sugano M; Nakazawa H; Yanagisawa R; Uehara T; Honda T; Okumura N
    Int J Hematol; 2020 Jul; 112(1):96-104. PubMed ID: 32253663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain.
    Dear A; Brennan SO; Sheat MJ; Faed JM; George PM
    Haematologica; 2007 Nov; 92(11):e111-7. PubMed ID: 18024387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
    Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK
    Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfibrinogenemia-associated novel heterozygous mutation, Shanghai (FGA c.169_180+2 del), leads to N-terminal truncation of fibrinogen Aα chain and impairs fibrin polymerization.
    Zhou J; Ding Q; Wu W; Ouyang Q; Xie Y; Wu X; Lu Y; Dai J; Liang Q; Wang H; Wang X; Hu Y
    J Clin Pathol; 2017 Feb; 70(2):145-153. PubMed ID: 27555433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].
    Matthias FR; Krause WH; Ganssert S; Mueller K; Lasch HG
    Klin Wochenschr; 1977 Jun; 55(11):539-43. PubMed ID: 881774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen.
    Risman RA; Belcher HA; Ramanujam RK; Weisel JW; Hudson NE; Tutwiler V
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A naturally occurring antibody that inhibits fibrin polymerization.
    Hoots WK; Carrell NA; Wagner RH; Cooper HA; McDonagh J
    N Engl J Med; 1981 Apr; 304(15):857-61. PubMed ID: 7207522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.
    Luo M; Wei A; Xiang L; Yan J; Liao L; Deng X; Deng D; Cheng P; Lin F
    J Thromb Thrombolysis; 2018 Oct; 46(3):409-419. PubMed ID: 29869737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary dysfibrinogenemia.
    Bithell TC
    Clin Chem; 1985 Apr; 31(4):509-16. PubMed ID: 3978780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen BOE II: dysfibrinogenemia with bleeding and defective thrombin binding.
    Li Y; Liang Q; Wu W; Hu X; Wang H; Wang X; Ding Q
    Res Pract Thromb Haemost; 2023 Jul; 7(5):102145. PubMed ID: 37601017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method.
    Lefkowitz JB; DeBoom T; Weller A; Clarke S; Lavrinets D
    Am J Hematol; 2000 Mar; 63(3):149-55. PubMed ID: 10679806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
    Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
    Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
    Terasawa F; Kani S; Hongo M; Okumura N
    Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital dysfibrinogenemia: fibrinogen Detroit.
    Mammen EF; Prasad AS; Barnhart MI; Au CC
    J Clin Invest; 1969 Feb; 48(2):235-49. PubMed ID: 4974308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen and dysfibrinogenemia.
    Morse EE
    Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.